December 11, 2025 – Hasten Biopharmaceutical Co., Ltd. (“Hasten”) and Everest Medicines (HKEX 1952.HK, "Everest") together announced that Everest’s wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (“Everest Medicines China”), has entered into two strategic agreements with Hasten.

June 16th, 2025 – Shanghai — Hasten Biopharmaceutical Co., Ltd. (“Hasten”) announced today the completion of Market Authorization Transfers (MAT) for 11 major pharmaceutical products across several key Asia-Pacific markets, including Malaysia, Singapore, Philippines, Hong Kong S.A.R. (China), etc.. The transfers were carried out by its affiliated entity, Hasten Biopharmaceutics (Asia) Co., Ltd., during the first half of 2025. This accomplishment marks a strategic leap forward in Hasten’s regional expansion, reinforcing its commitments to building a robust, patient-centric commercial ecosystem in Asia-Pacific and bringing high-quality products and solutions to more patients.

On May 9th, the "2025 VBEF Future Healthcare & Pharmaceuticals Top 100 Exhibition," initiated and hosted by the VBData.cn, was grandly held at the Suzhou International Expo Center, where multiple prestigious rankings were unveiled.

We are pleased to announce that following the completion of the Marketing Authorization Holder (MAH) transfer for ‌Hasten’s Stilamin® (Somatostatin) in the Greater China and Switzerland, the product has upgraded its packaging after passing regulatory compliance procedures and been officially implemented across all authorized territories.

December 5th, 2024 – Shanghai, China. Aon Group, a leading global professional services firm, today announced it has released the China Best ESG Employers Award list for 2024. Hasten Biopharmaceutical Co., Ltd. (hereinafter referred to as Hasten) was awarded "2024 China Best ESG Employer Award" out of overall 186 companies.

On September 24, 2024, the 3rd Partner Exchange Conference hosted by Hasten Biopharmaceutical Co., Ltd. was grandly held in Shenzhen, Guangdong.